EC
MDGL icon

EcoR1 Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

EcoR1 Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-75,000
Closed -$34.4M – 35
2025
Q3 		$34.4M Hold
75,000
– – 1.65% 15
2025
Q2 		$22.7M Hold
75,000
– – 1.34% 17
2025
Q1 		$24.8M Hold
75,000
– – 1.47% 14
2024
Q4 		$23.1M Hold
75,000
– – 0.87% 24
2024
Q3 		$15.9M Hold
75,000
– – 0.54% 39
2024
Q2 		$21M Hold
75,000
– – 0.64% 34
2024
Q1 		$20M Buy
+75,000
New +$17.7M 0.51% 36
2018
Q3 		– Sell
-199,500
Closed -$55.8M – 52
2018
Q2 		$55.8M Buy
+199,500
New +$35M 5.31% 6
2018
Q1 		– Sell
-35,000
Closed -$3.21M – 33
2017
Q4 		$3.21M Buy
+35,000
New +$2M 0.36% 26

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EcoR1 Capital's MDGL Position: Q4 2025 in Review

EcoR1 Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 75,000 shares — an estimated $34.4M sold.

EcoR1 Capital first reported a position in MDGL in Q4 2017 and held it in 9 quarters. The position peaked at $55.8M in Q2 2018. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • EcoR1 Capital reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • EcoR1 Capital sold 75,000 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $34.4M.
  • EcoR1 Capital first reported a position in Madrigal Pharmaceuticals in Q4 2017 and held it in 9 quarters.
  • EcoR1 Capital's Madrigal Pharmaceuticals position peaked at $55.8M in Q2 2018.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on EcoR1 Capital's 13F filing for Q4 2025, filed 17 Feb 2026.